Skip to content
    Real-World Studies

    Health Insurance Disparities in Guideline-Concordant Breast Cancer Treatment and Overall Survival

    Le et alResearch Square (preprint)

    Health Insurance Disparities in Guideline-Concordant Breast Cancer Treatment and Overall Survival
    Preprint (not peer reviewed): In a population-based study of 200,080 women aged 18 years and older diagnosed with invasive breast cancer between 2014 and 2022 from the California Cancer Registry, public health insurance was associated with reduced adherence to guideline-concordant oncology care and diminished overall survival.
    Investigators evaluated quality metrics defined by the Commission on Cancer: receipt of breast-conserving surgery or mastectomy for AJCC stage I or II disease (Q1); radiation therapy within one year of diagnosis for women younger than 70 years receiving breast-conserving surgery (Q2); and radiation within one year of diagnosis for individuals with four or more positive regional lymph nodes after mastectomy (Q3). Adherence across the cohort varied widely by measure, reaching 95% to 96% for primary surgical resection (Q1), 76% for post-lumpectomy radiation (Q2), and 50% to 56% for post-mastectomy radiation (Q3).
    Multivariable logistic regression and Cox proportional hazards models stratified by age revealed persistent insurance-based treatment gaps following Affordable Care Act implementation. Among women aged 18 to 64 years, those covered by Medicaid or Medicare experienced lower odds of meeting all three quality metrics compared with privately insured patients (adjusted ORs: 0.52–0.68). In patients aged 65 years and older, Medicaid or Medicare coverage was associated with reduced adherence to Q1 and Q2 (ORs: 0.54–0.88), though adherence to Q2 among those with Medicare plus supplemental insurance remained comparable to private insurance. Across all quality measures, non-adherence was associated with worse overall survival.

    Key Takeaways

    • Women aged 18 to 64 years with Medicaid or Medicare versus private insurance were less likely to receive all three guideline-concordant quality measures (adjusted ORs: 0.52–0.68), with overall adherence reaching 95%–96% for primary surgery (Q1), 76% for post-lumpectomy radiation (Q2), and 50%–56% for post-mastectomy radiation (Q3).
    • Non-adherence to guideline-concordant care was associated with worse overall survival across all quality measures, and disparities persisted among women aged ≥ 65 years on Medicaid or Medicare for Q1 and Q2 (ORs: 0.54–0.88), although Q2 adherence for Medicare with supplemental insurance was similar to private insurance.
    Read the original sourceResearch Square (preprint)